Based on the Thelansis market insight report on Alport Syndrome (AS) which provides a clear understanding of disease area background, epidemiology, current and future competitions, the country-specific standard of care, and the complete market forecast for 2020 to 2030.


The annual incidence/ diagnosed cases of Alport Syndrome varies between 130,000 to 154,000 in the year 2020. ~80?ses had typical glomerular basement membrane (GBM) changes of AS, ~10% patients initially had pathology features of diffuse thinning of the GBM only, 14% patients showed pathology of focal segmental glomerulosclerosis (FSGS)




Comprehensive insight on patient segmentation based on Age, Sex, types (X-linked, Autosomal, and Digenic ), stages (Stage – 0, I, II, III, IV, V), Renal Manifestation Frequency (hematuria, proteinuria, end-stage renal disease, transplantation), Extrarenal Manifestation (sensorineural hearing loss, Ocular Lesions and others), Inheritance & Mutation (XLAS; COL4A5, ARAS; COL4A3, & COL4A4, ADAS; COL4A3 OR COL4A4) has been provided into the epidemiology (Incidence and Prevalence) section of the Alport Syndrome(AS) and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China




Considering Alport syndrome is an excellent model of CKD with proteinuria and fibrosis, orphan drug designation with premium pricing benefits, number of patients to be treated will be substantial and finally s no approved treatment several drug candidates are in Phase II and II/ III stages of development by various companies. Key assets among these are Bardoxolone Methyl; Reata Pharmaceuticals, RG-012; Sanofi/ Regulus/ Genzyme, BMP-7; Ember Therapeutics, VAR300; ZyVersa Therapeutics. The launch of key assets will positively impact the overall market till 2030. While there is a lot of competitive activity going on in the pipeline for AS, companies like Reata Pharmaceuticals; Bardoxolone Methyl holds Orphan drug designation by US FDA and EMA. Patients treated with bardoxolone experienced a significant increase in eGFR of 7.8 mL/min/1.73 m2 (n=18; p=0.003) at Week 12 compared to baseline and to be found significantly improves kidney functions and well-tolerated among the different cohort of treatments.


About Thelansis:

Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.


Other Reports:-

Stargardt Disease – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Lambert-Eaton Myasthenic Syndrome (LEMS)  – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Narcolepsy – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report  – 2020 To 2030

Huntington Disease – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030


Tags: Alport Syndrome, Stargardt Disease, Lambert-Eaton Myasthenic Syndrome, LEMS, Bardoxolone, VAR300, ZyVersa Therapeutics

See Campaign: https://thelansis.com/reports/alport-syndrome-market-outlook-report/#1590842689564-c6740a95-8726
Contact Information:
Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India Contact no.: +91(124) 404-1731 Sales office 183-Asylum Street Hartford, CT-06103, USA USA +1 (267) 244-6955, Email clientsupport@thelansis.com m.berg@thelansis.com

Menafn, Reportedtimes, PR-Wirein, iCN Internal Distribution, Research Newswire, English